Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a landmark collaboration between its Thermo Fisher Scientific Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and the University Health Network (UHN) in Toronto to explore uncharted areas in biomarker research. Led by Eleftherios Diamandis, M.D., Ph.D., the project team in Toronto will use Thermo Fisher Scientific’s powerful mass spectrometers, in collaboration with the BRIMS Center research team, in a first-of-its-kind effort to target proteins in cancer cells.
“A central goal of the Thermo Fisher BRIMS Center is to enable and participate in groundbreaking proteomics research that holds promise to make new, potentially lifesaving, discoveries,” said Marc N. Casper, chief operating officer of Thermo Fisher Scientific. “Dr. Diamandis and his team believe they can make a difference in the outcome of cancer patients within the next five years, and we're honored to play a part in unlocking that discovery.”
Using Thermo Scientific LTQ Orbitrap™ and Thermo Scientific Quantum Ultra™ mass spectrometry systems, Dr. Diamandis will be the first biochemist to search for biomarker proteins in the secreted fluids of cancer cell lines. He believes this innovative approach will accelerate the validation of biomarkers, targeted assays and, ultimately, the implementation of a reliable blood test for cancers such as breast and colon, among others.
“Our talented team is focused on making advancements in biomarker testing by looking in the most logical place, cancer cell lines,” said Dr. Diamandis, biochemist-in-chief at University Health Network. “We expect to find important clues locked inside those proteins. The quest to validate biomarkers is complex and challenging, but also a critical frontier in science. The day that doctors can discover the presence of cancer through a drop of patient’s blood will mark a revolutionary victory against a disease that takes 20,000 lives every day. We hope our work will make this reality arrive sooner.”
The BRIMS Center and UHN will also maintain a “cross-validation” workflow for the duration of the project to help legitimize new biomarkers that have been validated in Toronto. After the UHN team validates a cancer biomarker, they will send it to the BRIMS Center, which is also equipped with a Thermo Scientific Quantum Ultra mass spectrometer, for a second validation.
With more than 20 years of experience in cancer diagnostics, Dr. Diamandis is recognized around the world as a leading researcher in cancer biomarkers. In addition to his position at UHN, Dr. Diamandis is division head of clinical biochemistry in the department of laboratory medicine and pathobiology at the University of Toronto in Ontario.
The Thermo Fisher BRIMS Center, located in Cambridge, Mass., opened in 2004 with a mission to support the development of methodologies and applications for protein biomarker identification. Equipped with a full complement of Thermo Scientific mass spectrometers and staffed by a team of scientists with expertise in mass spectrometry, protein techniques and informatics, the BRIMS Center also develops leading software tools for proteomics research.
For more information about Thermo Fisher Scientific’s extensive line of mass spectrometers, please visit www.thermo.com/ms.
Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 28, 2008, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission (SEC) and available in the “Investors” section of our Website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers’ capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Media Contact Information:
Karen Kirkwood, 781-622-1306
Investor Contact Information:
Ken Apicerno, 781-622-1111
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here